A novel biomarker for gut leakage as a diagnostic tool for HIV disease progression

Investigating a novel plasma biomarker's potential for identifying gut leakage.

A simple and rapid approach to predicting quality and potency of monoclonal and natural antibodies in health and disease

Rapid simple and scalable assays for predicting antibody potency.

Accelerating ART initiation among Infants (AAMI Study)

This project will trial the POC VISITECT® CD4 test and POC LYNX HIV p24 early infant diagnostic test.

Access to affordable and accurate HIV-1 VL testing

Laboratory evaluation of a novel filter paper-based method of plasma separation for viral load testing.

Access to CD4 (VISITECT® CD4) testing among HIV-infected women in Kenya

An accessible CD4 (VISITECT® CD4) test for HIV-infected pregnant and postpartum women in Kenya.

ACCESS: STI and BBV surveillance system

ACCESS is a surveillance system that collates important information on a range of STIs and BBVs.

Antibody mAbs to destroy infection: engineering the next generation treatments

Applying discoveries from our state-of-the-art cancer mAb program to neutralize and destroy pathogens such as HIV and Malaria.

Broadly neutralising anti-HIV antibodies and Fc Receptor function

Defining the properties of anti-HIV antibodies for vaccine development and protection of pregnant women.

co-EC Study: Eliminating hepatitis C/HIV coinfection

Eliminating hepatitis C transmission by enhancing care and treatment among HIV co-infected individuals.

Community-Based Rapid HIV Testing Services

Evaluating a multi-site rapid HIV testing trial in South Australia and rural site in Bendigo, Victoria.

DARE C: ATAHC II Substudy

DARE-C aims to evaluate therapy duration using triple therapy (PEG-IFN/RBV/TPV).

Developing new HIV disease progression tests

This project will develop prognostic tools to identify HIV+ persons at risk of rapid disease progression.

Development of a novel prophylactic vaccine candidate for HIV-1

A prophylactic vaccine represents the best strategy for blocking HIV-1 transmission.

Harm reduction among People who Inject Drugs in Myanmar

Aims to prevent the transmission of HIV among young people, students, migrant and transport workers.

HIV Prevention Cohort

Online cohort study of gay men in Victoria monitoring community-level change.

HIV testing among young men who have sex with men in Myanmar

Examining factors associated with HIV testing uptake among young men who have sex with men in Myanmar.

Optima decision science

Research and applications across disease areas to improve allocative efficiency.

Optima HIV: maximising the impact of HIV funding

Developing and applying software to maximise the impact of HIV funding around the world.

Plasma separator device for HIV viral load testing

Aimed at improving access to HIV viral load assays in resource-limited settings.

PrEPX: Rapid scale-up of HIV pre-exposure prophylaxis (PrEP)

Burnet is playing a crucial role in monitoring the outcomes of the PrEPX trial in Victoria.

PRONTO! Rapid HIV point-of-care testing in Victoria

The first rapid HIV test service in Victoria targeting gay men and men who have sex with men.

Sexual Health And Risk Prevention (SHARP) Study

Assessing responses to HIV prevention measures among Australian MSM.

TAIPAN: HIV cascade surveillance

Internationally novel project to create a linked surveillance system to monitor the HIV cascade for gay men

The Victorian Primary Care Network for Sentinel Surveillance on BBVs and STIs

The surveillance involves collection and linking of testing, demographic, and risk behaviour information.

Transmitted and acquired drug resistant HIV strains in Victoria, Australia

This project aims to document the rates and types of mutations associated with drug resistance being acquired by Victorian patients diagnosed with HIV and how this is changing over time.

VISITECT® CD4 point-of-care test

An affordable HIV point-of-care test developed by Burnet but licensed to Omega Diagnostics.